Brett S. Carver
Despite advances in the early detection and management of prostate cancer, hormone-refractory disease remains the second most common cause of male cancer deaths in the United States. Inhibition of the...Read More
Cory Abate-Shen, PhD
A Novel Human-to-Mouse-to-Human Approach for the Elucidation of Prostate Cancer Pathways and Druggable Targets—Identifying Shared Human and Mouse Molecules May Eliminate Traditional Limitations of Animal Models and Speed New Drug...Read More
Scott Williams, MD
Exploration of the Relationship between In Vivo Molecular Imaging, Cellular Response and Therapeutic Outcome in Irradiated Human Prostate Cancer A common treatment for localized prostate cancer is radiation therapy. Currently,...Read More
Matthew Smith, MD, PhD
Matthew Smith, M.D., Ph.D. is the Director of the Genitourinary Malignancies Program at the Massachusetts General Hospital Cancer Center and a Fellow at Dana-Farber Cancer Institute – Harvard Medical School....Read More
Justine Bruce
New therapeutics are urgently needed for hormone resistant prostate cancer when it emerges. Some patients with evidence of metastatic disease may receive chemotherapy while the same therapy for asymptomatic patients...Read More
Matthew Rettig, MD
A Nano-Structured Platform for Enhanced Detection of CTCs in Prostate Cancer Patients Circulating tumor cells (CTCs) are cancer cells that break away from either the primary tumor or metastatic lesions...Read More
Renata Pasqualini, PhD
Implications of Obesity in Prostate Cancer Recurrence and Progression- A Novel Fat-ablating Strategy to Overcome the Cancer Promoting Effects of Obesity Obese men are more likely to develop aggressive prostate...Read More
William Oh, MD
Predicting Response to Platinum Chemotherapy in Metastatic Castration-Resistant Prostate Cancer (CRPC) Using a Genomic Signature for "BRCAness" Every cell has DNA repair mechanisms that function to protect DNA from harmful...Read More
Timothy Yap
Technical advances have led to the identification and isolation of CTCs (Circulating Tumor Cells) from prostate cancer patients’ blood. Recent data have suggested that it is possible to use CTC...Read More
